Engineering exosomes to reshape the immune microenvironment in breast cancer: Molecular insights and therapeutic opportunities

Abstract

Surface modification of exosomes can improve the targeting specificity.

The engineered exosome-loaded immunomodulatory cargo regulates the tumour immune microenvironment.

Engineered exosomes are involved in the immune regulation of breast cancer.

Keywords

breast cancer / engineered exosomes / immune microenvironment / immunomodulation / immunotherapy

References

[1] KrugK, Jaehnig EJ, SatpathyS, et al. Proteogenomic landscape of breast cancer tumourigenesis and targeted therapy. Cell. 2020;183:1436-1456. e1431.

[2] Garcia-ArandaM, Redondo M. c. Cancers. 2019;11:1822.

[3] BarzamanK, KaramiJ, ZareiZ, et al. Breast cancer: biology, biomarkers, and treatments. Int Immunopharmacol. 2020;84:106535.

[4] MezniE, BehiK, GoncalvesA. Immunotherapy and breast cancer: an overview. Curr Opin Oncol. 2022;34:587-594.

[5] BasuA, Ramamoorthi G, JiaY, et al. Immunotherapy in breast cancer: current status and future directions. Adv Cancer Res. 2019;143:295-349.

[6] PengS, XiaoF, ChenM, Gao H. Tumour-microenvironment-responsive nanomedicine for enhanced cancer immunotherapy. Adv Sci. 2022;9:e2103836.

[7] KalluriR, LeBleuVS. The biology, function, and biomedical applications of exosomes. Science. 2020;367:eaau6977.

[8] ZhangL, YuD. Exosomes in cancer development, metastasis, and immunity. Biochim Biophys Acta Rev Cancer. 2019;1871:455-468.

[9] Kimiz-GebologluI, Oncel SS. Exosomes: large-scale production, isolation, drug loading efficiency, and biodistribution and uptake. J Control Release. 2022;347:533-543.

[10] KokVC, YuCC. Cancer-derived exosomes: their role in cancer biology and biomarker development. Int J Nanomed. 2020;15:8019-8036.

[11] FamiltsevaA, Jeremic N, TyagiSC. Exosomes: cell-created drug delivery systems. Mol Cell Biochem. 2019;459:1-6.

[12] WortzelI, DrorS, KenificCM, Lyden D. Exosome-mediated metastasis: communication from a distance. Dev Cell. 2019;49:347-360.

[13] LiangY, DuanL, LuJ, XiaJ. Engineering exosomes for targeted drug delivery. Theranostics. 2021;11:3183-3195.

[14] SalunkheS, Basak Dheeraj M, ChitkaraD, MittalA. Surface functionalization of exosomes for target-specific delivery and in vivo imaging & tracking: strategies and significance. J Control Release. 2020;326:599-614.

[15] ZhangM, HuS, LiuL, et al. Engineered exosomes from different sources for cancer-targeted therapy. Signal Transduct Target Ther. 2023;8:124.

[16] TaghikhaniA, Farzaneh F, SharifzadF, MardpourS, Ebrahimi M, HassanZM. Engineered tumour-derived extracellular vesicles: potentials in cancer immunotherapy. Front Immunol. 2020;11:221.

[17] RashedMH, Bayraktar E, HelalGK, et al. Exosomes: from garbage bins to promising therapeutic targets. Int J Mol Sci. 2017;18:538.

[18] ZhaoH, Achreja A, IessiE, et al. The key role of extracellular vesicles in the metastatic process. Biochim Biophys Acta Rev Cancer. 2018;1869:64-77.

[19] BebelmanMP, SmitMJ, PegtelDM, Baglio SR. Biogenesis and function of extracellular vesicles in cancer. Pharmacol Ther. 2018;188:1-11.

[20] WuK, XingF, WuSY, WatabeK. Extracellular vesicles as emerging targets in cancer: recent development from bench to bedside. Biochim Biophys Acta Rev Cancer. 2017;1868:538-563.

[21] HanQF, LiWJ, HuKS, et al. Exosome biogenesis: machinery, regulation, and therapeutic implications in cancer. Mol Cancer. 2022;21:207.

[22] MeldolesiJ. Exosomes and ectosomes in intercellular communication. Curr Biol. 2018;28:R435-R444.

[23] RaiborgC, Stenmark H. The ESCRT machinery in endosomal sorting of ubiquitylated membrane proteins. Nature. 2009;458:445-452.

[24] ColomboM, RaposoG, TheryC. Biogenesis, secretion, and intercellular interactions of exosomes and other extracellular vesicles. Annu Rev Cell Dev Biol. 2014;30:255-289.

[25] BishtT, Adhikari A, PatilS, DhoundiyalS. Bioconjugation techniques for enhancing stability and targeting efficiency of protein and peptide therapeutics. Curr Protein Pept Sci. 2023.

[26] JadhavS, KumarA, GulbakeA. Exosomes: recent advances and challenges as targeted therapeutic delivery vesicles. Crit Rev Ther Drug Carrier Syst. 2023;40:101-133.

[27] ChoiES, SongJ, KangYY, Mok H. Mannose-modified serum exosomes for the elevated uptake to murine dendritic cells and lymphatic accumulation. Macromol Biosci. 2019;19:e1900042.

[28] TianJ, HanZ, SongD, et al. Engineered exosome for drug delivery: recent development and clinical applications. Int J Nanomed. 2023;18:7923-7940.

[29] ZhangL, LinY, LiS, GuanX, JiangX. In situ reprogramming of tumour-associated macrophages with internally and externally engineered exosomes. Angew Chem Int Ed Engl. 2023;62:e202217089.

[30] ZhengW, HeR, LiangX, et al. Cell-specific targeting of extracellular vesicles through engineering the glycocalyx. J Extracell Vesicles. 2022;11:e12290.

[31] LiuW, Takahashi Y, MorishitaM, NishikawaM, Takakura Y. Development of CD40L-modified tumour small extracellular vesicles for effective induction of antitumour immune response. Nanomedicine. 2020;15:1641-1652.

[32] VulpisE, Loconte L, CassoneC, et al. Cross-dressing of multiple myeloma cells mediated by extracellular vesicles conveying MIC and ULBP ligands promotes NK cell killing. Int J Mol Sci. 2023;24:9467.

[33] JelencicV, Lenartic M, WensveenFM, PolicB. NKG2D: a versatile player in the immune system. Immunol Lett. 2017;189:48-53.

[34] ZingoniA, Molfetta R, FiondaC, et al. NKG2D and its ligands: “one for all, all for one”. Front Immunol. 2018;9:476.

[35] XuZ, TsaiHI, XiaoY, et al. Engineering programmed death ligand-1/cytotoxic t-lymphocyte-associated antigen-4 dual-targeting nanovesicles for immunosuppressive therapy in transplantation. ACS Nano. 2020;14:7959-7969.

[36] KleinpeterP, Remy-Ziller C, WinterE, et al. By binding CD80 and CD86, the vaccinia virus M2 protein blocks their interactions with both CD28 and CTLA4 and potentiates CD80 binding to PD-L1. J Virol. 2019;93:e00207-e00219.

[37] PiconMA, WangL, Da Fonseca FerreiraA, DongC, Marzouka GR. Extracellular Vesicles as Delivery Systems in Disease Therapy. Int J Mol Sci. 2023;24.

[38] ZhuT, ChenZ, JiangG, Huang X. sequential targeting hybrid nanovesicles composed of chimeric antigen receptor T-cell-derived exosomes and liposomes for enhanced cancer immunochemotherapy. ACS Nano. 2023;17:16770-16786.

[39] TongQ, LiK, HuangF, et al. Extracellular vesicles hybrid plasmid-loaded lipid nanovesicles for synergistic cancer immunotherapy. Mater Today Bio. 2023;23:100845.

[40] HanR, YuL, ZhaoC, et al. Inhibition of SerpinB9 to enhance granzyme B-based tumour therapy by using a modified biomimetic nanoplatform with a cascade strategy. Biomaterials. 2022;288:121723.

[41] ChengL, ZhangX, TangJ, Lv Q, LiuJ. Gene-engineered exosomes-thermosensitive liposomes hybrid nanovesicles by the blockade of CD47 signal for combined photothermal therapy and cancer immunotherapy. Biomaterials. 2021;275:120964.

[42] LiY, WuY, FederzoniEA, et al. CD47 cross-dressing by extracellular vesicles expressing CD47 inhibits phagocytosis without transmitting cell death signals. 2022;11.

[43] TiwariP, ShuklaRP, YadavK, et al. Dacarbazine-primed carbon quantum dots coated with breast cancer cell-derived exosomes for improved breast cancer therapy. J Control Release. 2023;365:43-59.

[44] YaoY, ZhangT, TangM. Toxicity mechanism of engineered nanomaterials: focus on mitochondria. Environ Pollut. 2023;343:123231.

[45] NguyenKG, VrabelMR, MantoothSM, et al. Localized interleukin-12 for cancer immunotherapy. Front Immunol. 2020;11:575597.

[46] RossowskaJ, AngerN, WegierekK, et al. Antitumour potential of extracellular vesicles released by genetically modified murine colon carcinoma cells with overexpression of interleukin-12 and shRNA for TGF-beta1. Front Immunol. 2019;10:211.

[47] McAndrewsKM, CheSPY, LeBleuVS, Kalluri R. Effective delivery of STING agonist using exosomes suppresses tumour growth and enhances antitumour immunity. J Biol Chem. 2021;296:100523.

[48] LiY, TianL, ZhaoT, Zhang J. A nanotherapeutic system for gastric cancer suppression by synergistic chemotherapy and immunotherapy based on iPSCs and DCs exosomes. Cancer Immunol Immunother. 2023;72:1673-1683.

[49] ChenY, WangL, ZhengM, et al. Engineered extracellular vesicles for concurrent anti-PDL1 immunotherapy and chemotherapy. Bioact Mater. 2022;9:251-265.

[50] WolfersJ, LozierA, RaposoG, et al. Tumour-derived exosomes are a source of shared tumour rejection antigens for CTL cross-priming. Nat Med. 2001;7:297-303.

[51] SunY, LiuJ. Potential of cancer cell-derived exosomes in clinical application: a review of recent research advances. Clin Ther. 2014;36:863-872.

[52] CostaA, Kieffer Y, Scholer-DahirelA, et al. Fibroblast heterogeneity and immunosuppressive environment in human breast cancer. Cancer Cell. 2018;33:463-479. e410.

[53] HuS, MaJ, SuC, et al. Engineered exosome-like nanovesicles suppress tumour growth by reprogramming tumour microenvironment and promoting tumour ferroptosis. Acta Biomater. 2021;135:567-581.

[54] DalmizrakA, Dalmizrak O. Mesenchymal stem cell-derived exosomes as new tools for delivery of miRNAs in the treatment of cancer. Front Bioeng Biotechnol. 2022;10:956563.

[55] DehneN, MoraJ, NamgaladzeD, Weigert A, BruneB. Cancer cell and macrophage cross-talk in the tumour microenvironment. Curr Opin Pharmacol. 2017;35:12-19.

[56] ChenY, SongY, DuW, GongL, ChangH, Zou Z. Tumour-associated macrophages: an accomplice in solid tumour progression. J Biomed Sci. 2019;26:78.

[57] SarodeP, Schaefer MB, GrimmingerF, SeegerW, SavaiR. Macrophage and tumour cell cross-talk is fundamental for lung tumor progression: we need to talk. Front Oncol. 2020;10:324.

[58] OstuniR, Kratochvill F, MurrayPJ, NatoliG. Macrophages and cancer: from mechanisms to therapeutic implications. Trends Immunol. 2015;36:229-239.

[59] ZajacAE, Czarnecka AM, RutkowskiP. The role of macrophages in sarcoma tumor microenvironment and treatment. Cancers. 2023;15:5294.

[60] ZhouX, ChenB, ZhangZ, et al. Crosstalk between tumour-associated macrophages and microRNAs: a key role in tumour microenvironment. Int J Mol Sci. 2022;23.

[61] ChenJ, WuF, HouE, ZengJ, LiF, GaoH. Exosomal microRNA therapy for non-small-cell lung cancer. Technol Cancer Res Treat. 2023;22:15330338231210731.

[62] GunassekaranGR, Poongkavithai Vadevoo SM, BaekMC, LeeB. M1 macrophage exosomes engineered to foster M1 polarization and target the IL-4 receptor inhibit tumour growth by reprogramming tumour-associated macrophages into M1-like macrophages. Biomaterials. 2021;278:121137.

[63] ShiaoSL, Ruffell B, DeNardoDG, FaddegonBA, ParkCC, CoussensLM. TH2-polarized CD4(+) T cells and macrophages limit efficacy of radiotherapy. Cancer Immunol Res. 2015;3:518-525.

[64] NieW, WuG, ZhangJ, et al. Responsive exosome nano-bioconjugates for synergistic cancer therapy. Angew Chem Int Ed Engl. 2020;59:2018-2022.

[65] KimH, ChaJ, JangM, Kim P. Hyaluronic acid-based extracellular matrix triggers spontaneous M2-like polarity of monocyte/macrophage. Biomater Sci. 2019;7:2264-2271.

[66] ShiQ, ZhaoL, XuC, ZhangL, ZhaoH. High molecular weight hyaluronan suppresses macrophage M1 polarization and enhances IL-10 production in PM(2.5)-induced lung inflammation. Molecules. 2019;24:1766.

[67] TammiMI, OikariS, Pasonen-SeppanenS, RillaK, Auvinen P, TammiRH. Activated hyaluronan metabolism in the tumour matrix—Causes and consequences. Matrix Biol. 2019;78-79:147-164.

[68] FengC, XiongZ, WangC, et al. Folic acid-modified Exosome-PH20 enhances the efficiency of therapy via modulation of the tumour microenvironment and directly inhibits tumour cell metastasis. Bioact Mater. 2021;6:963-974.

[69] LiQ, SongQ, ZhaoZ, et al. Genetically engineered artificial exosome-constructed hydrogel for ovarian cancer therapy. ACS Nano. 2023;17:10376-10392.

[70] YuY, LiT, OuM, et al. OX40L-expressing M1-like macrophage exosomes for cancer immunotherapy. J Control Release. 2023;365:469-479.

[71] WculekSK, CuetoFJ, MujalAM, Melero I, KrummelMF, SanchoD. Dendritic cells in cancer immunology and immunotherapy. Nat Rev Immunol. 2020;20:7-24.

[72] AndtbackaRH, Kaufman HL, CollichioF, et al. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol. 2015;33:2780-2788.

[73] KreutzM, TackenPJ, FigdorCG. Targeting dendritic cells-why bother?Blood. 2013;121:2836-2844.

[74] HuangL, RongY, TangX, et al. Engineered exosomes as an in situ DC-primed vaccine to boost antitumour immunity in breast cancer. Mol Cancer. 2022;21:45.

[75] XingJ, ZhangJ, WangJ. The immune regulatory role of adenosine in the tumour microenvironment. Int J Mol Sci. 2023;24:14928.

[76] ZareinejadM, Mehdipour F, Roshan-ZamirM, FaghihZ, Ghaderi A. Dual functions of T lymphocytes in breast carcinoma: from immune protection to orchestrating tumour progression and metastasis. Cancers. 2023;15:4771.

[77] KuererHM, NewmanLA, BuzdarAU, et al. Residual metastatic axillary lymph nodes following neoadjuvant chemotherapy predict disease-free survival in patients with locally advanced breast cancer. Am J Surg. 1998;176:502-509.

[78] Van TrappenPO, PepperMS. Lymphatic dissemination of tumour cells and the formation of micrometastases. Lancet Oncol. 2002;3:44-52.

[79] MunnDH, MellorAL. The tumour-draining lymph node as an immune-privileged site. Immunol Rev. 2006;213:146-158.

[80] DemariaMC, YeungL, PeetersR. Tetraspanin CD53 promotes lymphocyte recirculation by stabilizing L-selectin surface expression. iScience. 2020;23:101104.

[81] CroftM, SoT, DuanW, Soroosh P. The significance of OX40 and OX40L to T-cell biology and immune disease. Immunol Rev. 2009;229:173-191.

[82] FuN, XieF, SunZ, WangQ. The OX40/OX40L axis regulates T follicular helper cell differentiation: implications for autoimmune diseases. Front Immunol. 2021;12:670637.

[83] ChengQ, DaiZ, SmbatyanG, Epstein AL, LenzHJ, ZhangY. Eliciting anti-cancer immunity by genetically engineered multifunctional exosomes. Mol Ther. 2022;30:3066-3077.

[84] ShiX, ChengQ, HouT, et al. Genetically engineered cell-derived nanoparticles for targeted breast cancer immunotherapy. Mol Ther. 2020;28:536-547.

[85] WuK, LyuF, WuSY, et al. Engineering an active immunotherapy for personalized cancer treatment and prevention of recurrence. Sci Adv. 2023;9:eade0625.

[86] HenriquesB, MendesF, MartinsD. Immunotherapy in breast cancer: when, how, and what challenges?Biomedicines. 2021;9:1687.

[87] HannaA, BalkoJM. Breast cancer resistance mechanisms: challenges to immunotherapy. Breast Cancer Res Treat. 2021;190:5-17.

[88] TianY, LiS, SongJ, et al. A doxorubicin delivery platform using engineered natural membrane vesicle exosomes for targeted tumour therapy. Biomaterials. 2014;35:2383-2390.

[89] BourquinC, Pommier A, HotzC. Harnessing the immune system to fight cancer with Toll-like receptor and RIG-I-like receptor agonists. Pharmacol Res. 2020;154:104192.

[90] PengD, ChenL, SunY, et al. Melanoma suppression by quercein is correlated with RIG-I and type I interferon signaling. Biomed Pharmacother. 2020;125:109984.

[91] PengB, NguyenTM, JayasingheMK, et al. Robust delivery of RIG-I agonists using extracellular vesicles for anti-cancer immunotherapy. J Extracell Vesicles. 2022;11:e12187.

[92] SaxenaM, van der Burg SH, MeliefCJM, BhardwajN. Therapeutic cancer vaccines. Nat Rev Cancer. 2021;21:360-378.

[93] PaskehMDA, Entezari M, MirzaeiS, et al. Emerging role of exosomes in cancer progression and tumour microenvironment remodeling. J Hematol Oncol. 2022;15:83.

[94] MondalJ, Pillarisetti S, JunnuthulaV, et al. Hybrid exosomes, exosome-like nanovesicles and engineered exosomes for therapeutic applications. J Control Release. 2023;353:1127-1149.

[95] YildirimM, Yildirim TC, TurayN, et al. TLR ligand loaded exosome mediated immunotherapy of established mammary tumour in mice. Immunol Lett. 2021;239:32-41.

[96] PooresmaeilF, AndiS, Hasannejad-AslB, TakamoliS, Bolhassani A. Engineered exosomes: a promising vehicle in cancer therapy. Ther Deliv. 2023;14:775-794.

[97] SrivastavaS, Riddell SR. Chimeric antigen receptor T cell therapy: challenges to bench-to-bedside efficacy. J Immunol. 2018;200:459-468.

[98] MiliotouAN, Papadopoulou LC. CAR T-cell therapy: a new era in cancer immunotherapy. Curr Pharm Biotechnol. 2018;19:5-18.

[99] Gomes-SilvaD, RamosCA. Cancer immunotherapy using CAR-T cells: from the research bench to the assembly line. Biotechnol J. 2018;13:

[100] TangXJ, SunXY, HuangKM, et al. Therapeutic potential of CAR-T cell-derived exosomes: a cell-free modality for targeted cancer therapy. Oncotarget. 2015;6:44179-44190.

[101] FuW, LeiC, LiuS, et al. CAR exosomes derived from effector CAR-T cells have potent antitumour effects and low toxicity. Nat Commun. 2019;10:4355.

[102] LiY, XiaoF, ZhangA, et al. Oncolytic adenovirus targeting TGF-beta enhances anti-tumour responses of mesothelin-targeted chimeric antigen receptor T cell therapy against breast cancer. Cell Immunol. 2020;348:104041.

[103] YangP, CaoX, CaiH, et al. The exosomes derived from CAR-T cell efficiently target mesothelin and reduce triple-negative breast cancer growth. Cell Immunol. 2021;360:104262.

[104] TianT, LiangR, Erel-AkbabaG, et al. Immune checkpoint inhibition in GBM primed with radiation by engineered extracellular vesicles. ACS Nano. 2022;16:1940-1953.

[105] FanY, ZhouY, LuM, SiH, LiL, TangB. Responsive dual-targeting exosome as a drug carrier for combination cancer immunotherapy. Research. 2021;2021:9862876.

[106] AbdullaevB, RasyidSA, AliE, et al. Effective exosomes in breast cancer: focusing on diagnosis and treatment of cancer progression. Pathol Res Pract. 2024;253:154995.

[107] BoriachekK, MasudMK, PalmaC, et al. Avoiding pre-isolation step in exosome analysis: direct isolation and sensitive detection of exosomes using gold-loaded nanoporous ferric oxide nanozymes. Anal Chem. 2019;91:3827-3834.

[108] FarhanaFZ, UmerM, SaeedA, et al. Isolation and detection of exosomes using Fe₂O₃ nanoparticles. ACS Appl Nano Mater. 2021;4:1175-1186.

[109] KooKM, SodaN, ShiddikyMJA. Magnetic nanomaterial-based electrochemical biosensors for the detection of diverse circulating cancer biomarkers. Curr Opin Electrochem. 2021;25:100645.

[110] UrabeF, PatilK, RammGA, Ochiya T, SoekmadjiC. Extracellular vesicles in the development of organ-specific metastasis. J Extracell Vesicles. 2021;10:e12125.

RIGHTS & PERMISSIONS

2024 The Authors. Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.